Annual Total Liabilities
$2.11 M
+$158.00 K+8.11%
31 December 2022
Summary:
Nymox Pharmaceutical annual total liabilities is currently $2.11 million, with the most recent change of +$158.00 thousand (+8.11%) on 31 December 2022. During the last 3 years, it has fallen by -$91.00 thousand (-4.14%).NYMX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$2.37 M
+$267.00 K+12.67%
31 March 2023
Summary:
Nymox Pharmaceutical quarterly total liabilities is currently $2.37 million, with the most recent change of +$267.00 thousand (+12.67%) on 31 March 2023.NYMX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NYMX Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | -4.1% | +4.7% |
| 5 y5 years | +96.2% | +31.0% |
NYMX Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | ||||
| 5 y | 5 years | ||||
| alltime | all time | -86.8% | -85.1% |
Nymox Pharmaceutical Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $2.37 M(+12.7%) |
| Dec 2022 | $2.11 M(+8.1%) | $2.11 M(-11.0%) |
| Sept 2022 | - | $2.37 M(+5.6%) |
| June 2022 | - | $2.24 M(-14.7%) |
| Mar 2022 | - | $2.63 M(+34.8%) |
| Dec 2021 | $1.95 M(-11.3%) | $1.95 M(-14.1%) |
| Sept 2021 | - | $2.27 M(+15.5%) |
| June 2021 | - | $1.96 M(+33.8%) |
| Mar 2021 | - | $1.47 M(-33.3%) |
| Dec 2020 | $2.20 M(+7.7%) | $2.20 M(+15.9%) |
| Sept 2020 | - | $1.90 M(-10.5%) |
| June 2020 | - | $2.12 M(+9.8%) |
| Mar 2020 | - | $1.93 M(-5.4%) |
| Dec 2019 | $2.04 M(+90.0%) | $2.04 M(+12.6%) |
| Sept 2019 | - | $1.81 M(-7.1%) |
| June 2019 | - | $1.95 M(+14.0%) |
| Mar 2019 | - | $1.71 M(+59.3%) |
| Dec 2018 | $1.07 M(-51.8%) | $1.07 M(+26.5%) |
| Sept 2018 | - | $849.00 K(-47.4%) |
| June 2018 | - | $1.61 M(-19.2%) |
| Mar 2018 | - | $2.00 M(-10.4%) |
| Dec 2017 | $2.23 M(-3.0%) | $2.23 M(+24.3%) |
| Sept 2017 | - | $1.79 M(-12.2%) |
| June 2017 | - | $2.04 M(-29.0%) |
| Mar 2017 | - | $2.88 M(+25.1%) |
| Dec 2016 | $2.30 M(-25.0%) | $2.30 M(-24.9%) |
| Sept 2016 | - | $3.06 M(+17.5%) |
| June 2016 | - | $2.60 M(+2.7%) |
| Mar 2016 | - | $2.54 M(-17.3%) |
| Dec 2015 | $3.06 M(-45.3%) | $3.06 M(-19.0%) |
| Sept 2015 | - | $3.78 M(+17.9%) |
| June 2015 | - | $3.21 M(-0.4%) |
| Mar 2015 | - | $3.22 M(-42.5%) |
| Dec 2014 | $5.60 M(-20.2%) | $5.60 M(+1.2%) |
| Sept 2014 | - | $5.54 M(-15.5%) |
| June 2014 | - | $6.55 M(-8.1%) |
| Mar 2014 | - | $7.13 M(+1.5%) |
| Dec 2013 | $7.02 M(-23.6%) | $7.02 M(+1.1%) |
| Sept 2013 | - | $6.95 M(-15.5%) |
| June 2013 | - | $8.22 M(-6.6%) |
| Mar 2013 | - | $8.80 M(-4.4%) |
| Dec 2012 | $9.20 M(-20.5%) | $9.20 M(-6.8%) |
| Sept 2012 | - | $9.87 M(-5.0%) |
| June 2012 | - | $10.40 M(-2.8%) |
| Mar 2012 | - | $10.70 M(-7.5%) |
| Dec 2011 | $11.57 M(-27.5%) | $11.57 M(-3.7%) |
| Sept 2011 | - | $12.02 M(-5.2%) |
| June 2011 | - | $12.68 M(-4.8%) |
| Mar 2011 | - | $13.32 M(-16.5%) |
| Dec 2010 | $15.96 M | $15.96 M(+494.8%) |
| Sept 2010 | - | $2.68 M(+8.4%) |
| June 2010 | - | $2.48 M(+16.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2010 | - | $2.13 M(-16.2%) |
| Dec 2009 | $2.54 M(+23.6%) | $2.54 M(+15.8%) |
| Sept 2009 | - | $2.20 M(+0.4%) |
| June 2009 | - | $2.19 M(+4.7%) |
| Mar 2009 | - | $2.09 M(+1.6%) |
| Dec 2008 | $2.06 M(+58.9%) | $2.06 M(+37.9%) |
| Sept 2008 | - | $1.49 M(-2.4%) |
| June 2008 | - | $1.53 M(+9.7%) |
| Mar 2008 | - | $1.39 M(+7.6%) |
| Dec 2007 | $1.29 M(-39.6%) | $1.29 M(+19.4%) |
| Sept 2007 | - | $1.08 M(+11.0%) |
| June 2007 | - | $977.00 K(-40.8%) |
| Mar 2007 | - | $1.65 M(-23.0%) |
| Dec 2006 | $2.14 M(-14.5%) | $2.14 M(-2.8%) |
| Sept 2006 | - | $2.21 M(+24.4%) |
| June 2006 | - | $1.77 M(-32.8%) |
| Mar 2006 | - | $2.64 M(+5.3%) |
| Dec 2005 | $2.51 M(+22.1%) | $2.51 M(+12.6%) |
| Sept 2005 | - | $2.23 M(+7.8%) |
| June 2005 | - | $2.06 M(-2.6%) |
| Mar 2005 | - | $2.12 M(+3.2%) |
| Dec 2004 | $2.05 M(+19.1%) | $2.05 M(+11.4%) |
| Sept 2004 | - | $1.84 M(-12.7%) |
| June 2004 | - | $2.11 M(+48.5%) |
| Mar 2004 | - | $1.42 M(-17.5%) |
| Dec 2003 | $1.72 M(+17.2%) | $1.72 M(+25.7%) |
| Sept 2003 | - | $1.37 M(+50.9%) |
| June 2003 | - | $908.90 K(+10.2%) |
| Mar 2003 | - | $824.40 K(-44.0%) |
| Dec 2002 | $1.47 M(+96.9%) | $1.47 M(+62.5%) |
| Sept 2002 | - | $905.50 K(-13.6%) |
| June 2002 | - | $1.05 M(-2.8%) |
| Mar 2002 | - | $1.08 M(+44.2%) |
| Dec 2001 | $747.50 K(+130.9%) | $747.50 K(+5.4%) |
| Sept 2001 | - | $709.30 K(-6.5%) |
| June 2001 | - | $758.40 K(+287.1%) |
| Mar 2001 | - | $195.90 K(-39.5%) |
| Dec 2000 | $323.80 K(-61.1%) | $323.80 K(+17.1%) |
| Sept 2000 | - | $276.40 K(-46.1%) |
| June 2000 | - | $512.70 K(-15.1%) |
| Mar 2000 | - | $604.10 K(-27.5%) |
| Dec 1999 | $833.30 K(+176.8%) | $833.30 K(+317.1%) |
| Sept 1999 | - | $199.80 K(>+9900.0%) |
| June 1999 | - | $0.00(-100.0%) |
| Mar 1999 | - | $200.10 K(-33.5%) |
| Dec 1998 | $301.00 K(>+9900.0%) | $301.00 K(>+9900.0%) |
| Sept 1998 | - | $0.00(-100.0%) |
| June 1998 | - | $100.10 K(+0.2%) |
| Mar 1998 | - | $99.90 K(>+9900.0%) |
| Dec 1997 | $0.00 | $0.00(-100.0%) |
| Sept 1997 | - | $100.00 K(-50.0%) |
| June 1997 | - | $200.00 K |
FAQ
- What is Nymox Pharmaceutical annual total liabilities?
- What is the all time high annual total liabilities for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical quarterly total liabilities?
- What is the all time high quarterly total liabilities for Nymox Pharmaceutical?
What is Nymox Pharmaceutical annual total liabilities?
The current annual total liabilities of NYMX is $2.11 M
What is the all time high annual total liabilities for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high annual total liabilities is $15.96 M
What is Nymox Pharmaceutical quarterly total liabilities?
The current quarterly total liabilities of NYMX is $2.37 M
What is the all time high quarterly total liabilities for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high quarterly total liabilities is $15.96 M